GlobeNewswire (Wed, 7:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,019 people get CRIS articles and Market Currents by email alert.
Get email alerts on CRIS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (May 16, 2013)
-
GlobeNewswire (May 10, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 23, 2013)
-
-
GlobeNewswire (Mar 29, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 20, 2013)
-
GlobeNewswire (Feb 19, 2013)
-
GlobeNewswire (Feb 15, 2013)
-
GlobeNewswire (Feb 13, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
Curis: Next Week's Data Release Could Bring Volatility to SharesAlex Shadunsky • Fri, Jun 17, 2011 -
-
-
-
-
-
-
-
Casey Analyst Forecasts Explosive Biotech GrowthLife Sciences Report • Thu, Oct 11, 2012 -
-
-
-
-
Analyzing Thursday And Friday's Noteworthy Insider TradesGuruFundPicks • Mon, Apr 23, 2012
-
-
-
-
-
-
-
-
-
-
Curis' CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012
-
Curis, Inc. Q1 2010 Earnings Call TranscriptFri, May 7, 2010
-
Curis: The Wall Street Analyst Forum Presentation TranscriptThu, Sep 20, 2007
-
GlobeNewswire (Wed, 7:00AM)
-
GlobeNewswire (May 16, 2013)
-
GlobeNewswire (May 10, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 26, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 23, 2013)
-
GlobeNewswire (Mar 29, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 20, 2013)
-
GlobeNewswire (Feb 19, 2013)
-
GlobeNewswire (Feb 15, 2013)
-
GlobeNewswire (Feb 13, 2013)
-
GlobeNewswire (Jan 24, 2013)
-
GlobeNewswire (Dec 12, 2012)
-
GlobeNewswire (Dec 6, 2012)
-
GlobeNewswire (Dec 6, 2012)
-
GlobeNewswire (Nov 28, 2012)
CRIS vs. ETF Alternatives
Company Description
We are a drug discovery and development company that is committed to leveraging our innovative signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies. Biological signaling pathways, also referred to as signaling pathways, are prominent regulators of... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, April 30, 3:18 PM Curis (CRIS -8.6%) gets slammed after reporting a Q1 EPS loss that was worse than expected. Per share earnings were halved from what they were during the same quarter last year, largely due to higher interest expenses and Q112 being skewed by $10M in license fee revenues received from Genentech upon FDA approval of Erivedge. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, April 30, 7:09 AM Curis (CRIS): Q1 EPS of -$0.06 misses by $0.01. Revenue of $900K. (PR) Comment! [Earnings, Breaking News]
- Tuesday, April 30, 12:05 AM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS Comment! [Earnings]
- Monday, April 29, 5:30 PM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS 1 Comment [Earnings]
- Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]
-
Friday, April 26, 9:11 AM
Premarket gainers: LOGM +19%. AVNR +16%. SYNA +17%. QLIK +12%. CRIS +9%. DHI +7%. THRX +7%. MUX +7%. JCP +7%. CSTR +6%.
Losers: PKI -14%. SIMO -11%. BIDU -9%. KEG -8%. SDT -5%. Comment! [On the Move] -
Friday, March 1, 5:36 PM
After-hours top gainers, as of 5:15 p.m.: OUTD +13%. AVD +8%. ITMN +7%. JAKK +7%. GTI +6%.
After-hours top losers: CRIS -13%. BPZ -10%. AFCE -8%. CRM -7%. MKTG -7%. 4 Comments [On the Move] -
Friday, March 1, 1:01 PM
Midday top 10 gainers: GMXR +56%. RVLT +37%. MTG +24%. ANAC +15%. DECK +14%. NSPH +13%. KERX +13%. ATEC +13%. CRIS +12%. CIDM +12%.
Midday top 10 losers: SCMR -73%. AT -29%. RNIN -23%. LTBR -23%. FWLT -17%. MDR -14%. SUP -13%. SHIP -13%. MNOV -12%. CBMX -12%. Comment! [On the Move] - Wednesday, February 20, 11:26 AM Curis (CRIS -4.6%) slips after reporting a Q4 EPS loss that came up far short of consensus estimates this morning. Revenues were also below expectations, largely due to an absence of milestone payments, coming in at $1.69M, versus the analyst estimate of $2.28M. Earnings also declined Y/Y as well. In the same period last year, the company reported EPS of $0.07 on revenues of $14.1M. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, February 20, 7:03 AM Curis (CRIS): Q4 EPS of -$0.15 misses by $0.08. Revenue of $1.68M misses by $0.39M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, February 20, 12:05 AM Notable earnings before Wednesday’s open: AEE, AVA, CLH, CNK, CRIS, DISH, DTE, DVN, EXAS, GOV, GRMN, LEAP, LL, MGM, OC, PVR, SODA, TOL Comment! [Earnings]
- Tuesday, February 19, 5:30 PM Notable earnings before Wednesday’s open: AEE, AVA, CLH, CNK, CRIS, DISH, DTE, DVN, EXAS, GOV, GRMN, LEAP, LL, MGM, OC, PVR, SODA, TOL 1 Comment [Earnings]
- Thursday, February 14, 12:05 AM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
- Wednesday, February 13, 5:30 PM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
- Thursday, January 24, 9:23 AM Curis (CRIS) +4.2% premarket on news the drug developer has earned a $350K milestone payment from the Leukemia and Lymphoma Society after starting a Phase I clinical trial study of a refractory lymphoma and multiple myeloma treatment. 1 Comment [Healthcare, On the Move]
- Thursday, December 6, 2012, 11:48 AM Curis (CRIS -3.8%) trades lower today, despite the company's earlier announcement that it's been issued a patent covering a genus of compounds that includes Debio 0932, an orally-administered Heat Shock Protein 90 inhibitor, which is being developed by Curis' licensee Debiopharm. 1 Comment [Healthcare, On the Move]